Volume | 140,901 |
|
|||||
News | - | ||||||
Day High | 10.90 | Low High |
|||||
Day Low | 10.55 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
iTeos Therapeutics Inc | ITOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
10.59 | 10.55 | 10.90 | 10.80 | 10.60 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,620 | 140,901 | US$ 10.78 | US$ 1,519,255 | - | 8.20 - 18.24 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:20:01 | formt | 194 | US$ 10.80 | USD |
iTeos Therapeutics (ITOS) Options Flow Summary
iTeos Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
387.11M | 35.84M | - | 12.6M | -112.64M | -3.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
iTeos Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITOS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.27 | 11.22 | 10.01 | 10.66 | 348,619 | 0.53 | 5.16% |
1 Month | 13.80 | 13.80 | 10.01 | 11.82 | 276,468 | -3.00 | -21.74% |
3 Months | 10.04 | 13.80 | 9.70 | 11.34 | 288,477 | 0.76 | 7.57% |
6 Months | 9.35 | 13.80 | 8.7301 | 10.77 | 301,390 | 1.45 | 15.51% |
1 Year | 13.41 | 18.24 | 8.20 | 11.77 | 361,247 | -2.61 | -19.46% |
3 Years | 24.03 | 52.43 | 8.20 | 21.49 | 364,003 | -13.23 | -55.06% |
5 Years | 19.70 | 52.43 | 8.20 | 22.63 | 332,584 | -8.90 | -45.18% |
iTeos Therapeutics Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. |